Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $21.38 Average Price Target from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $21.38.

Several analysts have recently commented on the stock. Morgan Stanley decreased their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Friday, November 15th. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. BMO Capital Markets lowered their price target on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th.

Y-mAbs Therapeutics Stock Up 10.3 %

Shares of Y-mAbs Therapeutics stock opened at $11.88 on Thursday. Y-mAbs Therapeutics has a 1-year low of $5.45 and a 1-year high of $20.90. The firm’s 50-day moving average price is $13.57 and its two-hundred day moving average price is $12.82.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the prior year, the company posted ($0.18) earnings per share. Research analysts anticipate that Y-mAbs Therapeutics will post -0.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the transaction, the insider now directly owns 67,681 shares of the company’s stock, valued at $877,822.57. This trade represents a 30.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 22.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC boosted its position in shares of Y-mAbs Therapeutics by 433.4% during the third quarter. Barclays PLC now owns 69,222 shares of the company’s stock worth $910,000 after purchasing an additional 56,244 shares in the last quarter. Empire Financial Management Company LLC bought a new position in shares of Y-mAbs Therapeutics during the third quarter worth $210,000. Geode Capital Management LLC boosted its position in shares of Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after purchasing an additional 47,846 shares in the last quarter. State Street Corp boosted its position in shares of Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Finally, Caligan Partners LP boosted its position in shares of Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after purchasing an additional 613,175 shares in the last quarter. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.